-+ 0.00%
-+ 0.00%
-+ 0.00%
Based on the search results, I can see that Contineum Therapeutics just reported Q3 2026 earnings on Tuesday (November 3, 2026), missing estimates, and the company's partnered asset PIPE-307 failed its Phase 2 trial in September 2026. The company is now deferring the CTX-343 program to prioritize resources for PIPE-791, and maintains a cash runway through mid-2029.
Share
Listen to the news
Barchart +2.00% 03/2026 ($0.39) ($0.55) +29.09% 06/2026 ($0.40) ($0.46) +13.04% 09/2026 ($0.49) ($0.45) -8.89%
Quarter EPS Estimate EPS Actual Surprise % Beat/Miss
Dec 2025 $-0.50 $-0.49 +2.00% Beat
Mar 2026 $-0.55 $-0.39 +29.09% Beat
Jun 2026 $-0.46 $-0.40 +13.04% Beat
Sep 2026 $-0.45 $-0.49 -8.89% Miss

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Contineum typically reports earnings before the market opens, meaning Day 0 captures the first full trading session reaction to results, while Day +1 reflects follow-through momentum.

Earnings Date Day 0 Move Day 0 Range Day +1 Move Day +1 Range
2026-07-30 +$1.37 (+9.53%) $1.38 (9.60%) -$0.26 (-1.65%) $1.95 (12.41%)
2026-05-05 +$0.24 (+1.70%) $0.89 (6.27%) +$0.55 (+3.82%) $1.32 (9.17%)
2026-03-05 -$1.05 (-7.07%) $1.48 (9.96%) +$0.07 (+0.51%) $1.54 (11.19%)
2025-10-30 -$0.36 (-3.30%) $0.50 (4.59%) +$0.47 (+4.46%) $0.65 (6.21%)
2025-08-05 +$0.20 (+3.45%) $0.42 (7.24%) +$0.33 (+5.50%) $0.60 (9.97%)
2025-05-14 +$0.03 (+0.79%) $0.68 (17.85%) +$0.10 (+2.60%) $0.47 (12.24%)
2025-03-06 +$0.34 (+5.57%) $0.68 (11.15%) +$0.33 (+5.12%) $0.46 (7.14%)
2024-11-06 +$0.64 (+3.86%) $0.66 (3.95%) +$1.31 (+7.60%) $1.38 (7.98%)
Avg Abs Move 4.41% 8.82% 3.91% 9.54%

Contineum has exhibited volatile post-earnings price action, with an average absolute Day 0 move of 4.41% and Day +1 move of 3.91%. The most dramatic reaction came following the July 2026 report, when shares surged 9.53% on Day 0, though this was followed by a modest 1.65% decline the next session. The March 2026 report triggered a 7.07% decline on Day 0, while the most recent September 2026 report saw a relatively muted 3.30% drop.

The Day 0 range averages 8.82%, indicating substantial intraday volatility as investors digest results and management commentary. Day +1 ranges are even wider at 9.54%, suggesting that initial reactions often give way to reassessment as analysts publish notes and institutional investors adjust positions. The pattern shows that positive earnings surprises don't necessarily translate to sustained gains—the May 2026 beat produced only a 1.70% Day 0 move—while misses can be absorbed relatively well if accompanied by positive pipeline updates.

Earnings Date Day 0 Move Day 0 Range Day +1 Move Day +1 Range
2026-07-30 +9.53% 9.60% -1.65% 12.41%
2026-05-05 +1.70% 6.27% +3.82% 9.17%
2026-03-05 -7.07% 9.96% +0.51% 11.19%
2025-10-30 -3.30% 4.59% +4.46% 6.21%
2025-08-05 +3.45% 7.24% +5.50% 9.97%
2025-05-14 +0.79% 17.85% +2.60% 12.24%
2025-03-06 +5.57% 11.15% +5.12% 7.14%
2024-11-06 +3.86% 3.95% +7.60% 7.98%
Avg Abs Move 4.41% 8.82% 3.91% 9.54%

Part 2.2: Options Market Expected Move

Metric Value
Expiration Date 11/20/26 (DTE 16)
Expected Move $0.55 (5.66%)
Expected Range $9.22 to $10.32
Implied Volatility 185.45%

The options market is pricing a 5.66% expected move by the November 20 expiration (16 days out), which sits below the historical average Day 0 move of 4.41% but well below the 8.82% average Day 0 range. This suggests options traders are anticipating moderately elevated volatility but not the extreme swings seen in some prior quarters. The expected move range of $9.22 to $10.32 implies the market sees roughly equal probability of upside and downside, consistent with the current uncertainty around the company's strategic pivot and cash burn trajectory.

Metric Value
Expected Move ±5.66% ($0.55)
Upper Price Target $10.32
Lower Price Target $9.22
Days to Expiration 16 days
Average Volatility 185.45%

Part 3: What Analysts Are Saying

Contineum currently carries a consensus rating that translates to Hold, with an average recommendation of 4.13 on the five-point scale. The breakdown shows 4 Strong Buys, 1 Moderate Buy, and 3 Holds, with no sell ratings among the eight analysts covering the stock. However, sentiment has deteriorated over the past month, with the average recommendation declining from 4.38 as one analyst downgraded from Strong Buy to Hold.

The average price target of $22.00 implies substantial upside of approximately 125% from current levels, with estimates ranging from a low of $14.00 to a high of $30.00. This wide range reflects deep disagreement about PIPE-791's probability of success and the appropriate risk discount for a single-asset story. The most bullish analysts, including JonesTrading with a $30 target, emphasize the validated LPAR1 mechanism and PIPE-791's differentiated profile. More cautious voices, like Baird's $14 target following its October downgrade, cite competitive concerns and the binary nature of the Phase 2 readout expected in 2028.

The deteriorating sentiment trend is notable: one month ago, the consensus was more bullish at 4.38, with 5 Strong Buys versus the current 4. Recent downgrades from Robert W. Baird (Outperform to Neutral, $19 to $14) and price target cuts from Stifel ($28 to $23) and Morgan Stanley ($18 to $17) reflect growing caution following the PIPE-307 failure and mixed signals from Bristol's competing ALOFT trial. Despite the pullback in targets, the consensus still implies meaningful upside, suggesting analysts believe the market has overreacted to near-term setbacks and that PIPE-791's potential in a large, underserved market justifies the current valuation.

Part 4: Technical Picture

The Barchart Technical Opinion currently shows an 88% Sell signal, strengthening from 100% Sell last week and 40% Sell a month ago. This represents a Strengthening trend in bearish momentum, with the signal direction indicating deteriorating technical conditions heading into earnings.

Timeframe Analysis:

  • Short-term (50% Sell): Moderate sell signal suggests near-term pressure but not extreme bearish momentum
  • Medium-term (100% Sell): Strong sell signal indicates clear weakness in the intermediate timeframe as the stock digests recent setbacks
  • Long-term (100% Sell): Strong sell signal reflects sustained downtrend over the longer-term horizon, with shares down more than 40% over three months

Trend Characteristics: The Strong and Strengthening trend environment indicates building bearish momentum heading into earnings, with technical deterioration accelerating rather than stabilizing.

The stock is trading at $9.76, positioned above its 5-day ($9.55), 10-day ($9.07), and 20-day ($9.08) moving averages, suggesting a modest short-term bounce within a broader downtrend. However, the stock remains below all longer-term moving averages: the 50-day ($12.27), 100-day ($13.44), and 200-day ($13.52). This configuration—above short-term but below all intermediate and long-term averages—is characteristic of a bear market rally or dead-cat bounce rather than a genuine trend reversal.

Period Value Period Value
5-Day MA $9.55 50-Day MA $12.27
10-Day MA $9.07 100-Day MA $13.44
20-Day MA $9.08 200-Day MA $13.52

The technical setup heading into earnings is cautionary, with the stock trapped in a clear downtrend despite recent stabilization. The 28% gap between the current price and the 50-day moving average represents significant overhead resistance, while the clustering of the 50-, 100-, and 200-day averages in the $12-$14 range creates a formidable resistance zone. The strengthening sell signal and 100% bearish readings in both medium- and long-term timeframes suggest the path of least resistance remains lower absent a major positive catalyst. For bulls, a decisive break above the 20-day moving average with expanding volume would be the first sign of technical improvement, but the weight of evidence suggests traders should approach this earnings release with defensive positioning.

This article was generated using Barchart’s automated content technology and existing data APIs. As a result, we are able to provide readers with timely, actionable, in-depth analysis on more equities, allowing them to make more informed decisions. All information and data in this article is solely for informational purposes. For more information, please view the Barchart Disclosure Policy here. And, if you would like to report any inaccuracies, please contact news@barchart.com.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending